Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001638599-17-000127
Filing Date
2017-01-30
Accepted
2017-01-30 21:40:22
Documents
1
Period of Report
2017-01-26

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT doc4_4500.html 4  
1 PRIMARY DOCUMENT doc4_4500.xml 4 4129
  Complete submission text file 0001638599-17-000127.txt   5555
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Issuer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2265 MORNING STAR DRIVE PARK CITY UT 84060
Business Address
Fink Jeffrey Arvin (Reporting) CIK: 0001595930 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36357 | Film No.: 17559245